{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:17:25Z","timestamp":1740115045187,"version":"3.37.3"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.02.023","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T04:30:44Z","timestamp":1707712244000},"page":"2933-2936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimal interval for the administration of a pneumococcal polysaccharide vaccine following the administration of a pneumococcal conjugate vaccine"],"prefix":"10.1016","volume":"42","author":[{"given":"Philippe","family":"De Wals","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u00ebl","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.02.023_b0005","unstructured":"Public Health Agency of Canada. Canadian Immunization Guide. 2022. Available at: https:\/\/www.canada.ca\/en\/public-health\/services\/canadian-immunization-guide.html."},{"key":"10.1016\/j.vaccine.2024.02.023_b0010","doi-asserted-by":"crossref","unstructured":"Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013. IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-18. doi: 10.1093\/cid\/cit816. Erratum in: Clin Infect Dis. 2014 Jul 1;59(1):144.","DOI":"10.1093\/cid\/cit816"},{"key":"10.1016\/j.vaccine.2024.02.023_b0015","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Pilishvili T, Farrar JL, Leidner AJ, Gierke R, Prasad N, et al. Pneumococcal vaccine for adults aged \u226519 years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep 2023;72(No. RR-3):1\u201339. doi:http:\/\/dx.doi.org\/10.15585\/mmwr.rr7203a1.","DOI":"10.15585\/mmwr.rr7203a1"},{"key":"10.1016\/j.vaccine.2024.02.023_b0020","unstructured":"UK health Security Agency. The Green book. Chapter 5: Pneumococcal. 27 July 2023. Available at: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1178054\/Green_Book_Chapter_25_Pneumococcal_27_7_23.pdf."},{"issue":"8","key":"10.1016\/j.vaccine.2024.02.023_b0025","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1080\/21645515.2021.1888621","article-title":"Sequential administration of Prevnar 13\u2122 and PNEUMOVAX\u2122 23 in healthy participants 50 years of age and older","volume":"17","author":"Buchwald","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"9546","key":"10.1016\/j.vaccine.2024.02.023_b0030","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(06)69637-2","article-title":"Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study","volume":"368","author":"Whitney","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2024.02.023_b0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/599824","article-title":"Immunogenicity and reactogenicityof pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55\u201370 years of age","volume":"49","author":"Miernyk","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.02.023_b0040","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/vaccines10050795","article-title":"Immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults with and without immunosuppressive therapy","volume":"10","author":"Garcia Garrido","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.vaccine.2024.02.023_b0045","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1177\/09612033231153535","volume":"32","author":"Rezende","year":"2023","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.vaccine.2024.02.023_b0050","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3899\/jrheum.161407","article-title":"Initial serological response after prime-boost pneumococcal vaccination in rheumatoid arthritis patients: Results of a randomized controlled trial","volume":"44","author":"Nguyen","year":"2017","journal-title":"J Rheumatol"},{"issue":"37","key":"10.1016\/j.vaccine.2024.02.023_b0055","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1016\/j.vaccine.2013.04.065","article-title":"Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil","volume":"31","author":"Ho","year":"2013","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2024.02.023_b0060","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2024.02.023_b0065","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1086\/591629","article-title":"Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia","volume":"198","author":"Musher","year":"2008","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2024.02.023_b0070","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1086\/529142","article-title":"Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory","volume":"46","author":"de Roux","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2024.02.023_b0075","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1086\/606046","article-title":"The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50\u201380 years","volume":"49","author":"Goldblatt","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2024.02.023_b0080","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.vaccine.2013.04.084","article-title":"Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2024.02.023_b0085","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.vaccine.2014.02.002","article-title":"Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-na\u00efve adults 60\u201364 years of age","volume":"32","author":"Greenberg","year":"2014","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.vaccine.2024.02.023_b0090","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1016\/j.vaccine.2021.08.038","article-title":"Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged \u226550 years: A randomized phase III trial (PNEU-PATH)","volume":"39","author":"Song","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.023_b0095","article-title":"Immunogenicity, safety, and tolerability of V114, a 15-valent pneumococcal conjugate vaccine, in immunocompetent adults aged 18\u201349 years with or without risk factors for pneumococcal disease: A randomized Phase 3 trial (PNEU-DAY). Open Forum","author":"Hammitt","year":"202193605","journal-title":"Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.02.023_b0100","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.vaccine.2022.12.060","article-title":"Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-na\u00efve adults aged \u2265 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year","volume":"41","author":"Azuma","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.02.023_b0105","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/infdis\/173.1.256","article-title":"Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease","volume":"173","author":"Chan","year":"1996","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2024.02.023_b0110","doi-asserted-by":"crossref","first-page":"e46133","DOI":"10.1371\/journal.pone.0046133","article-title":"Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients","volume":"7","author":"Tobudic","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2024.02.023_b0115","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(07)70210-4","article-title":"Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?","volume":"7","author":"O'Brien","year":"2007","journal-title":"Lancet Infect Dis"},{"year":"2023","series-title":"Programme de surveillance du pneumocoque : rapport 2021\u201322","author":"Deceuninck","key":"10.1016\/j.vaccine.2024.02.023_b0120"},{"issue":"6","key":"10.1016\/j.vaccine.2024.02.023_b0125","first-page":"42","article-title":"Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales","volume":"2","author":"Djennad","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.02.023_b0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.arbres.2022.12.015","article-title":"Pneumococcal vaccination in adults: What can we learn from observational studies that evaluated PCV13 and PPV23 effectiveness in the same population?","volume":"59","author":"Dunne","year":"2023","journal-title":"Arch Bronconeumol"},{"issue":"3","key":"10.1016\/j.vaccine.2024.02.023_b0135","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/infdis\/jir750","article-title":"Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells","volume":"205","author":"Brynjolfsson","year":"2012","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2024.02.023_b0140","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/jis212","article-title":"Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells","volume":"205","author":"Clutterbuck","year":"2012","journal-title":"J Infect Dis"},{"issue":"2\/3","key":"10.1016\/j.vaccine.2024.02.023_b0145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.14745\/ccdr.v49i23a08","article-title":"on behalf of the National Advisory Committee on Immunization (NACI). Summary of the NACI statement on public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines","volume":"49","author":"Wierzbowski","year":"2023","journal-title":"CCDR"},{"issue":"1","key":"10.1016\/j.vaccine.2024.02.023_b0150","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/14760584.2021.1994858","article-title":"Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20","volume":"21","author":"Mt-Isa","year":"2022","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:53:48Z","timestamp":1725688428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24001634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24001634"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal interval for the administration of a pneumococcal polysaccharide vaccine following the administration of a pneumococcal conjugate vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}